Disillusioned Enlightenment for the Next Generation of Psychosis-Risk Research
Humans are not particularly good at predicting the future of new discoveries and tend to overestimate the impact of a new discovery in the short term, while largely underestimate the same in the long term. In the case of new technologies, the shape of this predictive curve has been described as the "Gartner Hype Cycle" 1 and includes 5 different stages: (1) innovative trigger, (2) peak of inflated expectations, (3) trough of disillusionment, (4) slope of enlightenment, and (5) plateau of productivity. Likewise, by analogy, about 2 decades ago the "At Risk Mental State" (also termed as "Clinical High Risk for Psychosis," CHR-P 2 ) criteria had been proposed as the breakthrough trigger for detection, prediction, and treatment of individuals at risk of developing serious mental disorders such as psychosis. The associated 2 decades of clinical research in this field have subsequently led to substantial knowledge advancements, and to a successful pragmatic implementation of indicated prevention in the history of psychiatry. Yet, over the recent few years, it has become apparent that the some of the initial expectations were certainly inflated and that the overall ability of the current approach for altering the course of psychosis is still relatively modest. 3 Inevitably, this has led to the rise of some disillusionment and of extreme polarities among researchers. On the one hand, some authors argue in favor of adequate evidence to completely abandon the CHR-P state, 4 on the other hand, the founders of the CHR-P state that there is enough evidence to reject any change and maintain the status quo. 5 The current special issue explores the area in-between these 2 polarities to recognize some key challenges while at the same time proposing ways to address them. The 3 studies presented herein are conceptually framed within an unstable phase of disillusioned enlightenment of psychosis-risk research. It is important to highlight that such an uncertain stage of knowledge has also been observed in other branches of clinical medicine such as cancer prevention. 6 We hope that this stage will ultimately pave the way toward a future plateau of knowledge and a refined CHR-P approach that could result in tangible benefits for clinicians, researchers and, more importantly, for patients and their families.
At Risk for What?
The first study published in this issue investigates the diagnostic boundaries of the CHR-P paradigm, which represents one of the most controversial issues in the field. Previous cohort studies confirmed that the CHR-P criteria are not diagnostically pluripotential, ie, they do not identify individuals at risk of developing any new/ incident nonpsychotic mental disorders. 7, 8 While most CHR-P individuals who will not develop psychosis show comorbid mental disorders at follow-up, the vast majority of these comorbid disorders is already present at baseline (ie, not representing emerging mental disorders). The first study published here further elaborated on these points by investigating whether comorbid mental disorders were more likely to persist in patients meeting the CHR-P criteria as compared to those assessed for CHR-P criteria but not meeting them. 9 However, the 6-month persistence of any nonpsychotic disorder was found to be comparable across the 2 groups (respectively, 54% and 57%). 9 All the findings above converge indicating that the current CHR-P criteria can only be used to predict the onset of new psychotic disorders. Although comorbid disorders clearly deserve clinical attention and treatment, the current CHR-P criteria are unlikely to allow preventative interventions for these nonpsychotic disorders. The next generation of research is thus required to complement the CHR-P assessment with extra criteria to predict and prevent other nonpsychotic mental disorders. For example, bipolar at risk criteria and psychometric tools are already available. 10 In line with these considerations, the founders of the CHR-P paradigm have just published a new assessment instrument which includes extra criteria to identify help-seeking young people at risk of developing a range of mental disorders beyond psychosis (eg, anxiety, stress, sleep, disturbance, substance abuse, personality traits, and cognitive problems).
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Can We Effectively Detect Individuals at Risk of Psychosis?
The biggest disillusion probably consists in the recent discovery that specialized CHR-P services, even when fully implemented in secondary mental health care, does not succeed with broad application. CHR-P services can only detect a tiny minority of individuals who will later develop of psychosis (about 5%, Figure 1) 12 and the vast majority (95%) of them are not referred to CHR-P services and assessed during their prodromal phase. The current CHR-P designation lacks pragmatic transdiagnostic power, which is defined as the ability to detect at risk individuals across different categories of mental disorders. The modest detection power presents serious clinical consequences. For example, it may hamper international clinical guidelines such as the Access and Waiting Times-Standard for Early Intervention and its NICE guidance. 13 Specifically, the guidance requires that CHR-P individuals are assessed and treated rapidly, and with evidence-based interventions. 13 The implementation of this NICE guidance is argued to "make a major difference" (foreword, p. 5), 13 based on the assumption that the nationwide extension of the current strategies for detecting CHR-P individuals would lead to improved outcomes for all first-episode psychosis. However, such an assumption is weak because these detection strategies are highly inefficient 14 ( Figure 1 ). The existing alternative of screening all patients with CHR-P instruments is logistically unfeasible in a large scale. A solution may be to deploy a 2-step assessment. In a first step, individualized transdiagnostic risk calculators could be used to detect putative at risk individuals in a large scale.
14 In a second step, refined prognostic clinical tools could be used in those detected by the risk calculator. The second study published in the current issue elaborates on such an opportunity by investigating clinical predictive criteria beyond the CHR-P ones. It compared the clinical significance of the DSM-5 attenuated psychosis syndrome (DSM-5 APS) vs standard CHR-P instruments such as the Comprehensive Assessment of At Risk Mental States (CAARMS) within individuals seeking help at specialized clinics. 15 The key result highlighted that the DSM-5-APS prognostic accuracy was acceptable (AUC 0.76 at 24 months) 15 and similar to the CAARMS (AUC 0.79 at 24 months 16 ). Although these findings need independent replication, they present Fig. 1 . Proportion of patients developing a first episode of ICD10 nonorganic psychosis in South London and the Maudsley SLaM NHS Foundation Trust (Lambeth and Southwark, n = 33 820) over the period 2008-2015 (n = 1001) detected (referred for a CHR-P assessment, evaluated for it and meeting CHR-P criteria, 5%) or undetected (95%) by the local CHR-P service which had been implemented in 2001 and which was conducting extensive outreach.
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promises for improving the detection of at risk individuals on several grounds. First, the DSM-5-APS assessment may be relatively easier to administer (23 min on average) as compared to the CHR-P psychometric tools. The latter are characterized by substantial operationalization and intake criteria differences and by heterogeneous subgroups 17 that clearly prevent their large-scale applicability in a broader context. Second, while the CHR-P is characterized by substantial epidemiological weaknesses, 18 the epidemiological prevalence of the DSM-5-APS category has already received some empirical validation. 19 A further avenue for improving the detection of at risk individuals, in particular from the community may be linked to the implementation of front-line mental health models for youth, 20 to facilitate the detection of young people.
Is the CHR-P State the Prototypical Stage of Risk for Psychosis?
Another untested assumption underlying the peak of expectations was that the CHR-P state would represent the prototypical stage of risk for the later development of psychosis. Extensive neurobiological research has been conducted on such an assumption, with the ultimate aim of identifying the holy grail of the Koplik Spots, 21 ie, key neurobiological markers indicative of an impending onset of psychosis. Such an assumption is threatened by a recent retrospective cohort study showing that not all (only about half) first-episode individuals would actually meet CHR-P features in the period preceding their first onset of the illness. 22 Aligned with these disillusionments, the third study published in the current issue investigated whether psychosis can be predicted outside the CHR-P construct. A systematic review of the risk of psychosis from depression risk syndromes, bipolar risk syndromes, and obsessive compulsive risk syndromes was conducted. The authors found that psychotic disorders can emerge outside the CHR-P paradigm, from clinical risk syndromes for incident nonpsychotic disorders, but at lower rates than in the CHR-P group. 23 If substantiated by future research, these current findings suggest that it may be useful to move beyond the current strategy of identifying individuals meeting just the CHR-P criteria.
Conclusion
In a previous special issue published in this journal, we have addressed the challenge of the clinical heterogeneity of the CHR-P state. In the current special issue, we complemented this work by addressing the problem of lack of diagnostic pluripotentiality, low detection power, and validity of the CHR-P paradigm as the prototypical state of risk for psychosis. In alignment with our disillusioned enlightenment approach, we concurrently proposed pragmatic avenues for a refined approach:
• Risk stratification within the CHR-P group, • New complementary criteria to predict outcomes other than psychosis, • Use of risk calculators to detect at risk cases, • Implementation of frontline mental health services for improving the access from the community, • Pragmatic evaluation of new diagnostic constructs such as the DSM-5-APS, • Further extensive research in clinical risk syndrome for the development of nonpsychotic mental disorders.
